Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 16/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483080 | 0.97 | OPRL1 (0.49) | OPRL1KCNH2OPRM1OPRK1 | |
| SCHEMBL6484977 | 0.83 | OPRL1 (0.52) | OPRL1KCNH2OPRM1OPRK1 | |
| SCHEMBL6497540 | 0.82 | OPRL1 (0.47) | OPRL1KCNH2OPRM1OPRK1PRKAG1 | |
| SCHEMBL6499128 | 0.82 | OPRL1 (0.53) | OPRL1KCNH2OPRM1OPRK1 | |
| SCHEMBL6496165 | 0.81 | OPRL1 (0.64) | OPRL1KCNH2OPRM1OPRK1NAMPT | |
| SCHEMBL6495978 | 0.81 | OPRL1 (0.46) | OPRL1KCNH2OPRM1OPRK1PRKAG1 | |
| SCHEMBL6486713 | 0.79 | OPRL1 (0.56) | OPRL1KCNH2OPRM1OPRK1 | |
| SCHEMBL6486948 | 0.79 | NAMPT (0.45) | OPRL1KCNH2OPRM1OPRK1BACE1 | |
| SCHEMBL6497547 | 0.79 | OPRL1 (0.51) | OPRL1KCNH2OPRM1OPRK1PRKAG1 | |
| SCHEMBL6499134 | 0.78 | OPRL1 (0.57) | OPRL1KCNH2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | OPRL1 2/4885KCNH2 126/4885OPRM1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.